Miroslava Zelenkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miroslava Zelenkova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Libor Vítek
1st Faculty of Medicine, Charles University, Praha, Czech Republic
3 shared publications Hendrik J. Vreman
Department of Pediatrics Stanford University School of Medicine Stanford CA USA
2 shared publications- Katerina Hadrava Vanova
Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 20814, Bethesda, MD, USA
2 shared publications - Lucie Muchová
Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and 1st Faculty of Medicine, Charles University, Prague, Czechia
2 shared publications Ronald J. Wong
Department of Pediatrics Stanford University School of Medicine Stanford CA USA
2 shared publications- Dalibor Černý
Department of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic
1 shared publication
Latest Publications
- 26 September 2019
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 150 (10) , 1731-1735
Determination of retinoic acid in human serum and plasma by high-performance liquid chromatography
- 26 September 2019
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 150 (10) , 1731-1735
Determination of retinoic acid in human serum and plasma by high-performance liquid chromatography
- Open Access
- 16 February 2015
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 19 (5) , 924-933
Protective effect of heme oxygenase induction in ethinylestradiol‐induced cholestasis
Estrogen‐induced cholestasis is characterized by impaired hepatic uptake and biliary bile acids secretion because of changes in hepatocyte transporter expression. The induction of heme oxygenase‐1 (HMOX1), the inducible isozyme in heme catabolism, is mediated via the Bach1/Nrf2 pathway, and protects livers from toxic, oxidative and inflammatory insults. However, its role in cholestasis remains unknown. Here, we investigated the effects of HMOX1 induction by heme on ethinylestradiol‐induced cholestasis and possible underlying mechanisms. Wistar rats were given ethinylestradiol (5 mg/kg s.c.) for 5 days. HMOX1 was induced by heme (15 μmol/kg i.p.) 24 hrs prior to ethinylestradiol. Serum cholestatic markers, hepatocyte and renal membrane transporter expression, and biliary and urinary bile acids excretion were quantified. Ethinylestradiol significantly increased cholestatic markers (P ≤ 0.01), decreased biliary bile acid excretion (39%, P = 0.01), down‐regulated hepatocyte transporters (Ntcp/Oatp1b2/Oatp1a4/Mrp2, P ≤ 0.05), and up‐regulated Mrp3 (348%, P ≤ 0.05). Heme pre‐treatment normalized cholestatic markers, increased biliary bile acid excretion (167%, P ≤ 0.05) and up‐regulated hepatocyte transporter expression. Moreover, heme induced Mrp3 expression in control (319%, P ≤ 0.05) and ethinylestradiol‐treated rats (512%, P ≤ 0.05). In primary rat hepatocytes, Nrf2 silencing completely abolished heme‐induced Mrp3 expression. Additionally, heme significantly increased urinary bile acid clearance via up‐regulation (Mrp2/Mrp4) or down‐regulation (Mrp3) of renal transporters (P ≤ 0.05). We conclude that HMOX1 induction by heme increases hepatocyte transporter expression, subsequently stimulating bile flow in cholestasis. Also, heme stimulates hepatic Mrp3 expression via a Nrf2‐dependent mechanism. Bile acids transported by Mrp3 to the plasma are highly cleared into the urine, resulting in normal plasma bile acid levels. Thus, HMOX1 induction may be a potential therapeutic strategy for the treatment of ethinylestradiol‐induced cholestasis.
- 16 February 2015
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 19 (5) , 924-933
Open AccessProtective effect of heme oxygenase induction in ethinylestradiol‐induced cholestasis
Estrogen‐induced cholestasis is characterized by impaired hepatic uptake and biliary bile acids secretion because of changes in hepatocyte transporter expression. The induction of heme oxygenase‐1 (HMOX1), the inducible isozyme in heme catabolism, is mediated via the Bach1/Nrf2 pathway, and protects livers from toxic, oxidative and inflammatory insults. However, its role in cholestasis remains unknown. Here, we investigated the effects of HMOX1 induction by heme on ethinylestradiol‐induced cholestasis and possible underlying mechanisms. Wistar rats were given ethinylestradiol (5 mg/kg s.c.) for 5 days. HMOX1 was induced by heme (15 μmol/kg i.p.) 24 hrs prior to ethinylestradiol. Serum cholestatic markers, hepatocyte and renal membrane transporter expression, and biliary and urinary bile acids excretion were quantified. Ethinylestradiol significantly increased cholestatic markers (P ≤ 0.01), decreased biliary bile acid excretion (39%, P = 0.01), down‐regulated hepatocyte transporters (Ntcp/Oatp1b2/Oatp1a4/Mrp2, P ≤ 0.05), and up‐regulated Mrp3 (348%, P ≤ 0.05). Heme pre‐treatment normalized cholestatic markers, increased biliary bile acid excretion (167%, P ≤ 0.05) and up‐regulated hepatocyte transporter expression. Moreover, heme induced Mrp3 expression in control (319%, P ≤ 0.05) and ethinylestradiol‐treated rats (512%, P ≤ 0.05). In primary rat hepatocytes, Nrf2 silencing completely abolished heme‐induced Mrp3 expression. Additionally, heme significantly increased urinary bile acid clearance via up‐regulation (Mrp2/Mrp4) or down‐regulation (Mrp3) of renal transporters (P ≤ 0.05). We conclude that HMOX1 induction by heme increases hepatocyte transporter expression, subsequently stimulating bile flow in cholestasis. Also, heme stimulates hepatic Mrp3 expression via a Nrf2‐dependent mechanism. Bile acids transported by Mrp3 to the plasma are highly cleared into the urine, resulting in normal plasma bile acid levels. Thus, HMOX1 induction may be a potential therapeutic strategy for the treatment of ethinylestradiol‐induced cholestasis.
- 1 December 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (12) , 911-912
Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis
- 1 December 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (12) , 911-912
Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis